Not So Different: A Podcast From The Center For Biosimilars

Show notes FDA Approves Stimufend, the US’ Sixth Pegfilgrastim Biosimilar https://www.centerforbiosimilars.com/view/fda-approves-stimufend-the-us-sixth-pegfilgrastim-biosimilar  FDA Approves Celltrion Biosimilar for Avastin, Vegzelma https://www.centerforbiosimilars.com/view/fda-approves-celltrion-biosimilar-for-avastin-vegzelma Oncology, Ophthalmology Biosimilars Progress in Europe https://www.centerforbiosimilars.com/view/oncology-ophthalmology-biosimilars-progress-in-europe Biosimilars Check-In: Canada Approves Third Etanercept; Prestige Withdraws Trastuzumab Application https://www.centerforbiosimilars.com/view/biosimilars-check-in-canada-approves-third-etanercept-prestige-withdraws-trastuzumab-application Coherus Rep Shares Competition Strategy for Adalimumab, Pegfilgrastim Biosimilars https://www.centerforbiosimilars.com/view/coherus-rep-previews-interchangeable-ranibizumab-adalimumb-launches-on-pro-competitor?seriesVid=5 Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts h